LUND, Sweden, June 27, 2022 /PRNewswire/ -- Immunovia will
present PanFAM-1 results today, June 27,
2022 at 13:00 pm CET.
Analysts, investors and media are invited to a webcast and
teleconference. The presentation slides will be available at
www.immunovia.com. See also press release published:
Philipp Matieu, CEO and
President, Thomas King, Medical
Director, and Jeff Borcherding, CEO
US operations, will present. The presentation will be held in
English and be followed by a Q&A session. You are welcome to
join via webcast or phone, see details below.
Telephone numbers and webcast
Ring any of the numbers below to participate via telephone.
Please dial in a few minutes before the presentation starts.
Sweden: +46 8 50 51 00 31
United Kingdom: +44 207 107 06
United States: +1 631 570 56
Link to the
To ask questions, it is necessary to dial in. A recording of the
presentation will be available on Immunovia's website.
For more information, please contact:
Senior Director Investor Relations and Corporate Communications
+46 736 36 35 74
The information was submitted for publication on June 27, 2022, at 09:00 am
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
The following files are available for download: